Literature DB >> 983997

Progress report: the activated coagulation time of whole blood (ACT).

P G Hattersley.   

Abstract

The activated coagulation time of whole blood (ACT) has, in the nearly ten years since its first description in the literature, proven itself one of the best laboratory tests for the control of heparin therapy, both for patients undergoing treatment for thromboembolic disease and for those on extracorporeal circulation. It is simple, largely free from subjective variation, precise, and quick. Prolongation of the ACT in the heparinized individual is directly proportional to the concentration of heparin in the blood, and the test accurately reflects the semilogarithmic disappearance of the anticoagulant effect in most patients. In addition, the test serves well as a bedside screening test for deficiencies of the intrinsic coagulation mechanism. The author summarizes the sutdies that have been carried out on this technic since its original description, and briefly presents three protocols for heparinization of patients who have thromboembolic disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 983997     DOI: 10.1093/ajcp/66.5.899

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass.

Authors:  A T Culliford; S N Gitel; N Starr; S T Thomas; F G Baumann; S Wessler; F C Spencer
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

3.  Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty.

Authors:  B Rath; D H Bennett
Journal:  Br Heart J       Date:  1990-01

4.  Clinical Experience with Routine Activated Coagulation Time Monitoring During Elective PTCA.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 5.  "In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.

Authors:  Vittorio Pavoni; Lara Gianesello; Duccio Conti; Piercarlo Ballo; Pietro Dattolo; Domenico Prisco; Klaus Görlinger
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

6.  Can We Rely on the Activated Clotting Time to Measure Heparin Anticoagulation? A Clinical Evaluation of Two ACT Monitors.

Authors:  Samuel Nilsson; Micael Appelblad; Staffan Svenmarker
Journal:  J Extra Corpor Technol       Date:  2020-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.